We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+19.81%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.35B
AUM Growth
+$99.6M
(+8%)
Cap. Flow
-$51.8M
Cap. Flow
% of AUM
-3.83%
Top 10 Holdings %
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$43.2M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$19.8M |
| 3 |
Baxter International
BAX
|
+$15.5M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$13.3M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$11.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$22.7M |
| 2 |
RLYP
RELYPSA INC COM
RLYP
|
+$18.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$17.6M |
| 4 |
CEMP
Cempra, Inc.
CEMP
|
+$16.2M |
| 5 |
SHPG
Shire pic
SHPG
|
+$8.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86% |
| 2 | Consumer Discretionary | 0.08% |
| 3 | Financials | 0.04% |
| 4 | Consumer Staples | 0.02% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EXAC
126
DELISTED
Exactech Inc
EXAC
| $195K | 0.01% |
+10,734
| New | +$191K |
|
127
UnitedHealth
UNH
$382B
| $193K | 0.01% |
+1,640
| New | +$192K |
|
|
AFAM
128
DELISTED
Almost Family Inc
AFAM
| $187K | 0.01% |
+4,889
| New | +$198K |
|
129
IQVIA
IQV
$40.7B
| $185K | 0.01% |
+2,698
| New | +$184K |
|
|
AMED
130
DELISTED
Amedisys
AMED
| $183K | 0.01% |
+4,648
| New | +$186K |
|
131
Community Health Systems
CYH
$382M
| $178K | 0.01% |
+8,136
| New | +$210K |
|
132
ImmunityBio
IBRX
$7.15B
| $173K | 0.01% |
+10,000
| New | +$148K |
|
133
Icon
ICLR
$13.7B
| $172K | 0.01% |
2,213
-418
| -16% | -$29.9K |
|
134
Centene
CNC
$30.5B
| $171K | 0.01% |
+5,186
| New | +$154K |
|
|
AMSG
135
DELISTED
Amsurg Corp
AMSG
| $170K | 0.01% |
+2,243
| New | +$178K |
|
136
Molina Healthcare
MOH
$10.4B
| $168K | 0.01% |
2,800
-88
| -3% | -$5.54K |
|
|
LHCG
137
DELISTED
LHC Group LLC
LHCG
| $168K | 0.01% |
3,705
-2,212
| -37% | -$101K |
|
|
LCI
138
DELISTED
Lannett Company, Inc.
LCI
| $168K | 0.01% |
1,046
+34
| +3% | +$5.58K |
|
|
INFI
139
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $157K | 0.01% |
20,000
| – | – |
|
|
FONR
140
DELISTED
Fonar
FONR
| $146K | 0.01% |
+8,473
| New | +$140K |
|
|
STRR
141
DELISTED
Star Equity Holdings
STRR
| $145K | 0.01% |
+500
| New | +$137K |
|
142
Lantheus
LNTH
$6.51B
| $131K | 0.01% |
+38,784
| New | +$140K |
|
143
Myriad Genetics
MYGN
$476M
| $108K | 0.01% |
2,500
| – | – |
|
144
Utah Medical Products
UTMD
$226M
| $107K | 0.01% |
+1,828
| New | +$104K |
|
|
CLLS
145
Cellectis
CLLS
$288M
| $93K | 0.01% |
2,996
-215,683
| -99% | -$6.54M |
|
|
NSPH
146
DELISTED
NANOSPHERE INC. COM NEW
NSPH
| $22K | ﹤0.01% |
35,379
| – | – |
|
|
AXDX
147
DELISTED
Accelerate Diagnostics
AXDX
| $16K | ﹤0.01% |
+75
| New | +$13.7K |
|
|
ACGN
148
DELISTED
Aceragen Inc
ACGN
| $14K | ﹤0.01% |
34
+23
| +209% | +$10.3K |
|
|
SCMP
149
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $13K | ﹤0.01% |
759
-7,146
| -90% | -$128K |
|
150
Capricor Therapeutics
CAPR
$380M
| $12K | ﹤0.01% |
400
| – | – |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q4 2015 Portfolio in Review
As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Perceptive Advisors withdrew a net $51.8M in Q4 2015, closing 45 positions and reducing 31 holdings. Its most notable exit was RELYPSA INC COM, an estimated $18.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Perceptive Advisors opened a new position in Allergan plc worth $45.3M.
- Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
- Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
- Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
- Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
- Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
- Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
- Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.
Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.